P L Giangrande

Summary

Affiliation: University of Oxford
Country: UK

Publications

  1. ncbi request reprint Haemophilia B: Christmas disease
    Paul Giangrande
    Oxford Haemophilia Centre and Thrombosis Unit, Churchill Hospital, OX3 7LJ, UK
    Expert Opin Pharmacother 6:1517-24. 2005
  2. ncbi request reprint Achievement of immune tolerance in a patient with haemophilia B and inhibitory antibodies, complicated by an anaphylactoid reaction
    N S Curry
    Oxford Haemophilia Centre and Thrombosis Unit, Oxford Radcliffe Hospitals, Oxford, UK
    Haemophilia 13:328-30. 2007
  3. doi request reprint Management of difficult-to-treat inhibitor patients
    P L F Giangrande
    Oxford Haemophilia and Thrombosis Centre, Churchill Hospital, Oxford, UK
    Haemophilia 16:52-7. 2010
  4. ncbi request reprint Gene therapy for hemophilia? No
    P L F Giangrande
    Oxford Haemophilia Centre, Thrombosis Unit, Churchill Hospital, Oxford OX3 7LK, UK
    J Thromb Haemost 2:1236-7. 2004
  5. ncbi request reprint Blood products for hemophilia: past, present and future
    Paul L F Giangrande
    Oxford Haemophilia Centre and Thrombosis Unit, Churchill Hospital, Oxford, UK
    BioDrugs 18:225-34. 2004
  6. doi request reprint Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors
    P L F Giangrande
    Oxford Haemophilia and Thrombosis Centre, Churchill Hospital, UK
    Haemophilia 15:501-8. 2009
  7. ncbi request reprint Treatment of patients with haemophilia and inhibitory antibodies
    P L F Giangrande
    Oxford Haemophilia Centre and Thrombosis Unit, Churchill Hospital, UK
    Indian J Pediatr 70:655-9. 2003
  8. ncbi request reprint Treatment of hemophilia: recombinant factors only? Yes
    P L F Giangrande
    Oxford Haemophilia Centre, Churchill Hospital, Oxford, UK
    J Thromb Haemost 1:214-5. 2003
  9. ncbi request reprint Six characters in search of an author: the history of the nomenclature of coagulation factors
    Paul L F Giangrande
    Oxford Haemophilia Centre and Thrombosis Unit, Churchill Hospital, Oxford, UK
    Br J Haematol 121:703-12. 2003
  10. ncbi request reprint Adverse events in the prophylaxis of haemophilia
    P L F Giangrande
    Oxford Haemophilia Centre and Thrombosis Unit, The Churchill Hospital, Oxford, UK
    Haemophilia 9:50-4; discussion 55-6. 2003

Collaborators

Detail Information

Publications18

  1. ncbi request reprint Haemophilia B: Christmas disease
    Paul Giangrande
    Oxford Haemophilia Centre and Thrombosis Unit, Churchill Hospital, OX3 7LJ, UK
    Expert Opin Pharmacother 6:1517-24. 2005
    ..Trials of gene therapy are also underway, but these are in the very early stages and will not be a realistic option for at least another 20 years...
  2. ncbi request reprint Achievement of immune tolerance in a patient with haemophilia B and inhibitory antibodies, complicated by an anaphylactoid reaction
    N S Curry
    Oxford Haemophilia Centre and Thrombosis Unit, Oxford Radcliffe Hospitals, Oxford, UK
    Haemophilia 13:328-30. 2007
    ..Immune tolerance was achieved by desensitisation with escalating doses of factor IX followed by the Malmö regimen...
  3. doi request reprint Management of difficult-to-treat inhibitor patients
    P L F Giangrande
    Oxford Haemophilia and Thrombosis Centre, Churchill Hospital, Oxford, UK
    Haemophilia 16:52-7. 2010
    ..Delegate opinions on the best treatment option for each scenario are described together with actual treatment given in real-life cases and its outcome...
  4. ncbi request reprint Gene therapy for hemophilia? No
    P L F Giangrande
    Oxford Haemophilia Centre, Thrombosis Unit, Churchill Hospital, Oxford OX3 7LK, UK
    J Thromb Haemost 2:1236-7. 2004
  5. ncbi request reprint Blood products for hemophilia: past, present and future
    Paul L F Giangrande
    Oxford Haemophilia Centre and Thrombosis Unit, Churchill Hospital, Oxford, UK
    BioDrugs 18:225-34. 2004
    ..Transgenic animals are a potential source of therapeutic materials. Several trials of gene therapy for hemophilia are already underway...
  6. doi request reprint Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors
    P L F Giangrande
    Oxford Haemophilia and Thrombosis Centre, Churchill Hospital, UK
    Haemophilia 15:501-8. 2009
    ..Although the initial cost of product to cover surgery such as arthroplasty is high, it needs to be borne in mind that this may be offset in subsequent years by savings resulting from avoidance of bleeding episodes in the affected joint...
  7. ncbi request reprint Treatment of patients with haemophilia and inhibitory antibodies
    P L F Giangrande
    Oxford Haemophilia Centre and Thrombosis Unit, Churchill Hospital, UK
    Indian J Pediatr 70:655-9. 2003
    ..It is possible to suppress antibody production with immune tolerance, which is successful in approximately 85% of cases and relapse is rare...
  8. ncbi request reprint Treatment of hemophilia: recombinant factors only? Yes
    P L F Giangrande
    Oxford Haemophilia Centre, Churchill Hospital, Oxford, UK
    J Thromb Haemost 1:214-5. 2003
  9. ncbi request reprint Six characters in search of an author: the history of the nomenclature of coagulation factors
    Paul L F Giangrande
    Oxford Haemophilia Centre and Thrombosis Unit, Churchill Hospital, Oxford, UK
    Br J Haematol 121:703-12. 2003
  10. ncbi request reprint Adverse events in the prophylaxis of haemophilia
    P L F Giangrande
    Oxford Haemophilia Centre and Thrombosis Unit, The Churchill Hospital, Oxford, UK
    Haemophilia 9:50-4; discussion 55-6. 2003
    ..Whilst sporting activities are to be encouraged, there is a potential for significant trauma in children with prophylaxis, as plasma coagulation factor levels remain far below normal with the usual regimens...
  11. ncbi request reprint The WFH Haemophilia Centre Twinning Programme: 10 years of growth, 1993-2003
    P L F Giangrande
    World Federation of Haemophilia, Montreal, Quebec, Canada
    Haemophilia 9:240-4. 2003
    ..In addition, continuing support and advice are available from the WFH regional programme officers...
  12. ncbi request reprint Viral pharmacovigilance study of haemophiliacs receiving porcine factor VIII
    P L F Giangrande
    Oxford Haemophilia Centre and Thrombosis Unit, Churchill Hospital, Oxford, UK
    Haemophilia 8:798-801. 2002
    ..In conclusion, there was no evidence of transmission of PPR or other marker porcine virus associated with the use of porcine FVIII concentrate (Hyate: C)...
  13. ncbi request reprint Air travel and thrombosis
    Paul L F Giangrande
    Oxford Haemophilia Centre and Thrombosis Unit, Churchill Hospital, Oxford OX3 7LJ, UK
    Br J Haematol 117:509-12. 2002
  14. ncbi request reprint World Federation of Haemophilia programs in developing countries
    Paul L F Giangrande
    World Federation of Haemophilia, Montreal, Quebec, Canada
    Semin Thromb Hemost 31:555-60. 2005
    ..The WFH is also involved in fostering discussion on key issues such as safety and supply of blood products...
  15. ncbi request reprint Safety and efficacy of KOGENATE Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs)
    P L F Giangrande
    Oxford Haemophilia Centre, Churchill Hospital, Oxford, UK
    Haemophilia 8:19-22. 2002
    ..The incidence of inhibitor formation is not different to that observed with other recombinant or plasma-derived products...
  16. ncbi request reprint Variation in inhibitor reactivity in acquired haemophilia A with different concentrates
    K Sukhu
    Oxford Haemophilia Centre, The Churchill Hospital, Oxford, UK
    Clin Lab Haematol 22:287-90. 2000
    ..All but one antibody had very low reactivity with porcine FVIII. Further work will be required to establish whether concentrates manifesting a low level of in vitro reactivity with the inhibitor have a better haemostatic effect in vivo...
  17. ncbi request reprint Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV
    Sarah C Darby
    Clinical Trial Service Unit, University of Oxford, Oxford, UK
    Blood 110:815-25. 2007
    ..There was no evidence of any death from variant Creutzfeldt-Jakob disease or from conditions that could be confused with it...
  18. ncbi request reprint The impact of HIV on mortality rates in the complete UK haemophilia population
    Sarah C Darby
    AIDS 18:525-33. 2004
    ..To estimate the effect of HIV-1 infection on subsequent mortality in a complete population...